Herpes Zoster (Shingles): Varicella Reactivation, Postherpetic Neuralgia, and Antiviral Management

Clinical Overview

Herpes zoster (shingles) results from reactivation of latent varicella-zoster virus (VZV) residing in dorsal root ganglia following primary varicella infection (chickenpox). This painful dermatomal vesicular eruption affects 30% of population by age 90, with highest incidence >60 years as immune senescence permits viral reactivation. Early antiviral therapy dramatically reduces disease severity, postherpetic neuralgia (PHN) incidence, and systemic complications compared to historical no-treatment or delayed-treatment approaches.

Epidemiology

Herpes zoster incidence: 3-4 per 1000 person-years overall; 10-15 per 1000 person-years aged 60+. Lifetime risk 30% (approach 50% by age 85). Immunosuppression increases risk 10-20 fold (HIV CD4 <200, chemotherapy, transplant recipients, systemic corticosteroids). Recurrent zoster develops 1-5% (higher if immunocompromised). Complications: postherpetic neuralgia (PHN, pain >3 months post-rash) develops 10-15% overall but 50% aged >60 years; ophthalmic zoster (trigeminal distribution) in 10-15% with 10-30% developing ocular complications (keratitis, uveitis); disseminated zoster in immunocompromised. Zoster sine herpete (PHN without rash) occurs in 2-4%. Associated systemic manifestations: vasculopathy (stroke risk 1.7-fold in ophthalmic zoster within 1 year), meningitis (5% with ophthalmic involvement), encephalitis (<1%).

Pathophysiology

Varicella-zoster virus reactivation occurs when CD4+ T-cell immunity wanes with age or immunosuppression. Virus replicates within dorsal root ganglion neurons, producing inflammatory response with cytokine release (IL-6, TNF-alpha, substance P). Anterograde axonal transport delivers virions to skin causing dermatomal vesicular eruption with intense inflammatory infiltrate. Central sensitization (prolonged nociceptor activation) and peripheral nerve injury establish chronic pain (PHN): demyelination, axonal degeneration, altered GABA and glutamate signaling in dorsal horn. Duration of acute viremia, extent of inflammation, and magnitude of nerve injury predict PHN development; older age, severe acute pain, and higher lesion burden associate with increased PHN risk.

Clinical Presentation

Prodromal phase (48-72 hours): dermatomal pain, burning, or paresthesias often mistaken for musculoskeletal pain, cardiac ischemia, or other pathology. Fever, malaise, headache in 10%. Acute phase: grouped vesicles on erythematous base in dermatomal distribution (90% involve thoracic dermatomes T5-T12; 10-15% ophthalmic V1; 5% sacral). Vesicles rupture within 48-72 hours creating pustules progressing to crusting. Severe dermatomal pain (60-80%), pruritus/dysesthesia (30-40%), regional lymphadenopathy. Healing over 2-4 weeks with permanent pigmentary changes in 10% (post-inflammatory hyperpigmentation or hypopigmentation). PHN: burning pain, allodynia (pain with light touch), dysesthesia persisting months to years after rash resolution; profoundly impacts quality of life (depression 20%, anxiety 15%).

Diagnosis

Diagnosis clinical based on unilateral dermatomal vesicular eruption with prodromal pain. Confirmation: viral culture (sensitivity 95-99% if fluid from fresh vesicle, <50% if pustules/crusts), PCR (sensitivity 95%, gold standard increasingly used), Tzanck smear (multinucleated giant cells, supports diagnosis), or serology (IgM for acute infection, though IgM less specific). Ophthalmic zoster requires ophthalmology examination to assess for keratitis, anterior uveitis, secondary glaucoma.

Treatment Algorithm

Acute Zoster: Early antiviral initiation critical (within 72 hours of rash onset for maximal efficacy). Acyclovir 800mg 5 times daily x 7-10 days, valacyclovir 1000mg 3 times daily x 7-10 days (superior bioavailability, preferred), or famciclovir 500mg 3 times daily x 7-10 days. IV acyclovir 10mg/kg q8h reserved for disseminated zoster, CNS involvement, immunocompromised with severe disease. Efficacy: reduces acute pain duration by 1-2 weeks, acute pain severity by 20-40%, and PHN risk by 40-50% (from 45% to 20-25% in aged >60 with early treatment).

Acute Pain Management: Essential component of therapy. NSAIDs (ibuprofen 600mg 4 times daily, naproxen 500mg twice daily) for 1-2 weeks. Add topical lidocaine 5% patches applied to affected dermatome 12 hours daily reduces pain 30% locally. Gabapentin 300-3600mg daily (divided dosing) started early (within first week) and continued 1-3 months reduces acute pain and PHN incidence by 30-40%. Initial 300mg daily titrating by 300mg every 1-2 days to effect (maximum 3600mg); elderly tolerate 1800-2400mg better. Pregabalin 150-600mg daily alternative with similar efficacy. Topical capsaicin 0.075% cream applied 3-5 times daily provides modest benefit (pain reduction 20-30%). Opioids reserved for severe pain unresponsive to other modalities due to addiction/dependence risk; if prescribed, concurrent gabapentin/pregabalin reduces opioid requirements.

Ophthalmic Zoster: Treat as medical emergency. Acyclovir 800mg 5 times daily x 7-10 days (or valacyclovir 1000mg 3 times daily). Add topical antivirals (vidarabine 3% ointment 5 times daily) and cycloplegic agents (cyclopentolate 1% 3 times daily) if anterior uveitis present. Topical corticosteroid (prednisolone acetate 1%) only if anterior uveitis confirmed (avoid if dendritic keratitis present—risk of geographic ulceration). Urgent ophthalmology referral mandatory.

Postherpetic Neuralgia Management: Initiated as pain persists beyond acute phase (>4 weeks). Gabapentin 300-3600mg daily (divide dosing TID; titrate up), pregabalin 150-600mg daily (divide BID-TID), or SNRIs (venlafaxine 75-225mg daily, duloxetine 60mg daily). Topical lidocaine patches 12 hours daily provide localized relief. Topical capsaicin 0.075% or 8% patches applied 30-60 minutes. Opioids as adjunct only if inadequate response (morphine 5-30mg daily divided dosing, long-acting formulations for chronic pain). Tricyclic antidepressants (amitriptyline 10-75mg nightly) alternative first-line with pain and sleep benefit. Avoid abrupt discontinuation; taper gradually to prevent withdrawal.

Prognosis

Zoster: acute pain resolves 2-4 weeks in 50%; however, 40% persistent pain at 3 months, 10-15% at 1 year. Antiviral therapy reduces PHN incidence 40-50%, gabapentin/pregabalin further 30%, cumulative reduction of PHN risk. Early vaccination (recombivax zoster >90% efficacy in preventing zoster; 50% reduction in PHN severity if breakthrough zoster develops) substantially improves population outcomes. Disseminated zoster (immunocompromised): mortality <1% with IV acyclovir but significant morbidity.

When to See a Dermatologist

Dermatologists recognize zoster, initiate antiviral therapy, optimize acute pain management, and manage PHN. Refer ophthalmic zoster to ophthalmology urgently. Coordinate chronic pain management with neurology if PHN severe/refractory.

Frequently Asked Questions

Q: Can I give shingles to others?
A: You cannot give shingles directly. However, virus from your blisters can infect non-immune individuals (no prior chickenpox/vaccine) causing chickenpox, not shingles. Cover lesions and maintain hand hygiene. Non-immune persons should avoid direct contact.

Q: How long until pain goes away?
A: Acute pain typically resolves 2-4 weeks with antiviral therapy. However, 40% experience lingering pain at 3 months (PHN). Early gabapentin/pregabalin initiation prevents PHN in 30-40%. PHN pain may persist months to years; however, 50% improve by 12 months.

Q: Should I get vaccinated?
A: Yes. Recombivax (newer vaccine) >90% effective preventing zoster in those aged 50+. Reduces severity if breakthrough zoster develops. Recommended for all adults 50+. Safe even with prior zoster (reduces recurrence risk).

Q: Why is pain so severe?
A: Zoster involves nerve inflammation directly. Viral replication in nerve cells and intense inflammatory response cause severe acute pain. Central sensitization perpetuates pain beyond acute phase (PHN), making it difficult to treat. Early antiviral/gabapentin therapy interrupts this process.

References